Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)
Status: | Completed |
---|---|
Conditions: | Asthma |
Therapuetic Areas: | Pulmonary / Respiratory Diseases |
Healthy: | No |
Age Range: | 18 - 90 |
Updated: | 1/25/2018 |
Start Date: | December 2004 |
End Date: | February 2008 |
The purpose of this trial is to determine whether regularly scheduled use of an inhaled
long-acting beta agonist (salmeterol) in the setting of concomitant use of inhaled
corticosteroids (beclomethasone hydroflouroalkane (HFA) inhaler) will have a detrimental
effect on asthma control in people who bear the B16-Arg/Arg genotype of the beta-2 adrenergic
receptor gene, as compared to people with asthma of similar severity who bear the B16-Gly/Gly
genotype.
long-acting beta agonist (salmeterol) in the setting of concomitant use of inhaled
corticosteroids (beclomethasone hydroflouroalkane (HFA) inhaler) will have a detrimental
effect on asthma control in people who bear the B16-Arg/Arg genotype of the beta-2 adrenergic
receptor gene, as compared to people with asthma of similar severity who bear the B16-Gly/Gly
genotype.
BACKGROUND:
The purpose of this study is to compare the effects of a long-acting beta agonist in patients
with asthma receiving inhaled corticosteroids who express two distinct polymorphisms of the
beta-2 adrenergic receptor.
DESIGN NARRATIVE:
Participants were homozygous for arginine or glycine at the 16th amino-acid position of the
β-2 adrenergic receptor (B16 Arg/Arg or B16 Gly/Gly). Individuals were matched against their
opposite genotype by forced expiratory volume in one second (FEV1) and race. Matched
participants entered an 8-week run-in period. This is a 62-week crossover design where
subjects receive the following therapies:
- Beclomethasone HFA (240 µg twice a day (BID)) + as-needed (PRN) albuterol: 8-week run-in
- Beclomethasone HFA (240 µg BID) + salmeterol (50 µg BID) + PRN ipratropium bromide + PRN
albuterol: 18-week treatment period
- Beclomethasone HFA (240 µg BID) + PRN albuterol: 8-week run-out
- Beclomethasone HFA (240 µg BID) + placebo salmeterol + PRN ipratropium bromide + PRN
albuterol: 18-week treatment period
- Beclomethasone HFA (240 µg BID) + PRN albuterol: 10-week run-out
The order of treatments received during the two treatment periods is randomized.
The purpose of this study is to compare the effects of a long-acting beta agonist in patients
with asthma receiving inhaled corticosteroids who express two distinct polymorphisms of the
beta-2 adrenergic receptor.
DESIGN NARRATIVE:
Participants were homozygous for arginine or glycine at the 16th amino-acid position of the
β-2 adrenergic receptor (B16 Arg/Arg or B16 Gly/Gly). Individuals were matched against their
opposite genotype by forced expiratory volume in one second (FEV1) and race. Matched
participants entered an 8-week run-in period. This is a 62-week crossover design where
subjects receive the following therapies:
- Beclomethasone HFA (240 µg twice a day (BID)) + as-needed (PRN) albuterol: 8-week run-in
- Beclomethasone HFA (240 µg BID) + salmeterol (50 µg BID) + PRN ipratropium bromide + PRN
albuterol: 18-week treatment period
- Beclomethasone HFA (240 µg BID) + PRN albuterol: 8-week run-out
- Beclomethasone HFA (240 µg BID) + placebo salmeterol + PRN ipratropium bromide + PRN
albuterol: 18-week treatment period
- Beclomethasone HFA (240 µg BID) + PRN albuterol: 10-week run-out
The order of treatments received during the two treatment periods is randomized.
Inclusion Criteria:
- Male or female, ages 18 and older
- Clinical history consistent with asthma
- For subjects regularly using inhaled corticosteroids, FEV1 50% of predicted,
methacholine PC20 FEV1 16 mg/ml or 12% and 200 ml, improvement in FEV1 after 2 puffs
of inhaled albuterol
- For subjects not regularly using inhaled corticosteroids, FEV1 40% of predicted,
methacholine PC20 FEV1 8 mg/ml or 12% and 200 ml, improvement in FEV1 after 2 puffs of
inhaled albuterol
- Genotype eligibility (determined during screening)
Exclusion Criteria:
- Smoker (total smoking history must be less than 10 pack years)
- Significant unstable medical condition other than asthma
- History of life-threatening asthma requiring treatment with intubation and mechanical
ventilation in the past 10 years
- Pregnant or lactating
We found this trial at
7
sites
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
Click here to add this to my saved trials
Click here to add this to my saved trials
University of Wisconsin-Madison In achievement and prestige, the University of Wisconsin-Madison has long been recognized...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
1 Medical Center Blvd
Winston-Salem, North Carolina 27157
Winston-Salem, North Carolina 27157
336-716-2011
Wake Forest University Health Sciences Welcome to Wake Forest Baptist Medical Center, a fully integrated...
Click here to add this to my saved trials